In the first case, preclinical studies showed that GBA augmentation via adeno-associated virus reduced α-synuclein aggregation and cognitive deficits in the mice models of GD-related synucleinopathy and decreased α-synuclein levels in SNCA mice models [31]. This evidence concerns the gene SNCA and synucleinopathy.